Defective and excessive immunities in pediatric diseases

Luigi Daniele Notarangelo, Alberto Tommasini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Inflammatory and autoimmune diseases are classically considered as disorders arising from hyper-activation of immunity and hence are treated with drugs that suppress the lymphocyte activation and inflammation. Although this strategy has proven useful to cure symptoms, it rarely can heal the disease and long-term treatments are usually needed. Inflammatory and autoimmune diseases frequently occur also in patients with primary immune deficiency disease, proving that immune hyper-activation may paradoxically arise from defective function of immune genes. In these cases, the phenotype of hyper-activation is believed to reflect the attempts of the immune system to compensate for immune defects. Recent data suggest that similar mechanisms could be involved also in the pathogenesis of some multifactorial disorders, such as Crohn's disease and systemic lupus erythematosus. Based on these considerations, novel therapies could be developed to cure severe autoimmune and inflammatory disorders, not only by aiming to hyper-activation but as well by focusing on the possible underlying immune defects.

Original languageEnglish
Pages (from-to)5729-5734
Number of pages6
JournalCurrent Pharmaceutical Design
Volume18
Issue number35
DOIs
Publication statusPublished - 2012

Fingerprint

Autoimmune Diseases
Immunity
Pediatrics
Lymphocyte Activation
Crohn Disease
Systemic Lupus Erythematosus
Immune System
Inflammation
Phenotype
Therapeutics
Pharmaceutical Preparations
Genes
Immune Deficiency Disease

Keywords

  • Anti-inflammatory drugs
  • Autoimmunity
  • Chronic inflammatory diseases
  • Immune tolerance
  • Inflammation
  • Primary immunodeficiency diseases
  • Regulatory T cells

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Defective and excessive immunities in pediatric diseases. / Notarangelo, Luigi Daniele; Tommasini, Alberto.

In: Current Pharmaceutical Design, Vol. 18, No. 35, 2012, p. 5729-5734.

Research output: Contribution to journalArticle

Notarangelo, Luigi Daniele ; Tommasini, Alberto. / Defective and excessive immunities in pediatric diseases. In: Current Pharmaceutical Design. 2012 ; Vol. 18, No. 35. pp. 5729-5734.
@article{f61aa3d5706c4198880a74578ac67bf7,
title = "Defective and excessive immunities in pediatric diseases",
abstract = "Inflammatory and autoimmune diseases are classically considered as disorders arising from hyper-activation of immunity and hence are treated with drugs that suppress the lymphocyte activation and inflammation. Although this strategy has proven useful to cure symptoms, it rarely can heal the disease and long-term treatments are usually needed. Inflammatory and autoimmune diseases frequently occur also in patients with primary immune deficiency disease, proving that immune hyper-activation may paradoxically arise from defective function of immune genes. In these cases, the phenotype of hyper-activation is believed to reflect the attempts of the immune system to compensate for immune defects. Recent data suggest that similar mechanisms could be involved also in the pathogenesis of some multifactorial disorders, such as Crohn's disease and systemic lupus erythematosus. Based on these considerations, novel therapies could be developed to cure severe autoimmune and inflammatory disorders, not only by aiming to hyper-activation but as well by focusing on the possible underlying immune defects.",
keywords = "Anti-inflammatory drugs, Autoimmunity, Chronic inflammatory diseases, Immune tolerance, Inflammation, Primary immunodeficiency diseases, Regulatory T cells",
author = "Notarangelo, {Luigi Daniele} and Alberto Tommasini",
year = "2012",
doi = "10.2174/138161212803530943",
language = "English",
volume = "18",
pages = "5729--5734",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "35",

}

TY - JOUR

T1 - Defective and excessive immunities in pediatric diseases

AU - Notarangelo, Luigi Daniele

AU - Tommasini, Alberto

PY - 2012

Y1 - 2012

N2 - Inflammatory and autoimmune diseases are classically considered as disorders arising from hyper-activation of immunity and hence are treated with drugs that suppress the lymphocyte activation and inflammation. Although this strategy has proven useful to cure symptoms, it rarely can heal the disease and long-term treatments are usually needed. Inflammatory and autoimmune diseases frequently occur also in patients with primary immune deficiency disease, proving that immune hyper-activation may paradoxically arise from defective function of immune genes. In these cases, the phenotype of hyper-activation is believed to reflect the attempts of the immune system to compensate for immune defects. Recent data suggest that similar mechanisms could be involved also in the pathogenesis of some multifactorial disorders, such as Crohn's disease and systemic lupus erythematosus. Based on these considerations, novel therapies could be developed to cure severe autoimmune and inflammatory disorders, not only by aiming to hyper-activation but as well by focusing on the possible underlying immune defects.

AB - Inflammatory and autoimmune diseases are classically considered as disorders arising from hyper-activation of immunity and hence are treated with drugs that suppress the lymphocyte activation and inflammation. Although this strategy has proven useful to cure symptoms, it rarely can heal the disease and long-term treatments are usually needed. Inflammatory and autoimmune diseases frequently occur also in patients with primary immune deficiency disease, proving that immune hyper-activation may paradoxically arise from defective function of immune genes. In these cases, the phenotype of hyper-activation is believed to reflect the attempts of the immune system to compensate for immune defects. Recent data suggest that similar mechanisms could be involved also in the pathogenesis of some multifactorial disorders, such as Crohn's disease and systemic lupus erythematosus. Based on these considerations, novel therapies could be developed to cure severe autoimmune and inflammatory disorders, not only by aiming to hyper-activation but as well by focusing on the possible underlying immune defects.

KW - Anti-inflammatory drugs

KW - Autoimmunity

KW - Chronic inflammatory diseases

KW - Immune tolerance

KW - Inflammation

KW - Primary immunodeficiency diseases

KW - Regulatory T cells

UR - http://www.scopus.com/inward/record.url?scp=84870229947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870229947&partnerID=8YFLogxK

U2 - 10.2174/138161212803530943

DO - 10.2174/138161212803530943

M3 - Article

C2 - 22726115

AN - SCOPUS:84870229947

VL - 18

SP - 5729

EP - 5734

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 35

ER -